# Semaglutide Treatment in Type 1 Diabetes

> **NCT06909006** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Nordsjaellands Hospital** · enrollment: 122 (estimated)

## Conditions studied

- Obesity in Diabetes
- Obesity/Therapy
- Type 1 Diabetes Mellitus (T1DM)
- Insulin Sensitivity/Resistance
- Semaglutide
- Lipidomics
- Metabolomics
- Weight Loss
- Glycemic Control for Diabetes Mellitus

## Interventions

- **DRUG:** Semaglutide 2.4mg
- **DRUG:** Semaglutide placebo

## Key facts

- **NCT ID:** NCT06909006
- **Lead sponsor:** Nordsjaellands Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06909006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06909006, "Semaglutide Treatment in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06909006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*